DK2897956T3 - Nye bicykliske pyridinoner - Google Patents
Nye bicykliske pyridinoner Download PDFInfo
- Publication number
- DK2897956T3 DK2897956T3 DK13792085.6T DK13792085T DK2897956T3 DK 2897956 T3 DK2897956 T3 DK 2897956T3 DK 13792085 T DK13792085 T DK 13792085T DK 2897956 T3 DK2897956 T3 DK 2897956T3
- Authority
- DK
- Denmark
- Prior art keywords
- mmol
- alkyl
- pharmaceutically acceptable
- methyl
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Claims (27)
1. Forbindelse med strukturen af formel I eller et farmaceutisk acceptabelt salt deraf:
hvor: X er et 5- til 14-leddet heteroaryl indeholdende 1-3 heteroatomer; R1 er hydrogen, halogen, CrC6alkyl, C3-C6cycloalkyl eller C2-C6alkenyl; hvor alkylet, cycloalkylet eller alkenylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af fluor, hydroxyl og CrC6alkoxy; A er et C3-C6cycloalkyl eller et 4- til 10-leddet heterocycloalkyl; hvor cycloalkylet eller heterocycloalkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af halogen og CrC6alkyl; R2a og R2b ved hver forekomst uafhængigt er hydrogen, fluor, cyano, -CF3, CrC6alkyl, C2-C6alkenyl, C3-C6cycloalkyl, CrCsbicycloalkyl, C2-C6alkynyl eller phenyl; hvor alkylet, alkenylet, cycloalkylet, bicycloalkylet, alkynylet eller phenylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af cyano, CrC3alkyl og fluor; eller R2a og R2b sammen med carbonet, til hvilket de er bundet, danner et 3- til 5-leddet cycloalkyl eventuelt substitueret med et til tre af R8; R3 er hydrogen, halogen, CrC6alkyl, C2-C6alkenyl, -(C(R10)2)t-(C3-Cecycloalkyl), -(C(R10)2)t-(4- til 10-leddet heterocycloalkyl), -(C(R10)2)t-(C6-C10aryl), -(C(R10)2)r(5-til 10-leddet heteroaryl) eller -(C(R10)2)t-OR12; hvor alkylet, alkenylet, cycloalkylet, heterocycloalkylet, arylet eller heteroarylet eventuelt er substitueret med et til fem af R11; R4a og R4b hvert uafhængigt er hydrogen, -CF3 eller CrC6alkyl, hvor alkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af -CF3, cyano og fluor; eller R4a og R4b sammen med carbonet, til hvilket de er bundet, danner et 3- til 5-leddet cycloal-kyl, hvor cycloalkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af -CF3, cyano, fluor og CrC6alkyl; R5a og R5b ved hver forekomst hvert uafhængigt er hydrogen, -CF3 eller Cr Cealkyl, hvor alkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af -CF3, cyano og fluor; eller R5a og R5b sammen med carbonet, til hvilket de er bundet, danner et 3-til 5-leddet cycloalkyl, hvor cycloalkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af -CF3, cyano, fluor og CrC6alkyl; R6, R7 og R8 hvert uafhængigt er hydrogen, -CF3, cyano, halogen, C-rC6alkyl eller -OR9; forudsat at R6 og R7 ikke begge kan være -OFI; R9 er hydrogen, CrC6alkyl eller -CF3; hvor alkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af cyano og fluor; hvert R10 uafhængigt er hydrogen, halogen, cyano, -CF3, CrC6alkyl eller -SF5; hvor alkylet eventuelt er substitueret med et til tre fluor; hvert R11 uafhængigt er hydrogen, halogen, -CF3, -SF5, -Si(CH3)3, -OR12, Cr C6alkyl, C2-C6alkenyl, C2-C6alkynyl, -(C(R10)2),-(C3-C6cycloalkyl), -(C(R10)2),-(C6-C10aryl) eller -(C(R10)2)t-(5- til 10-leddet heteroaryl), hvor -Si(CH3)3, alkylet, alkenylet, alkynylet, cycloalkylet, arylet eller heteroarylet eventuelt er substitueret med en til fem substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af halogen og -CF3; hvert R12 er hydrogen, CrC6alkyl, -(C(R13)2)n-(C3-C6cycloalkyl), -(C(R13)2)n-(4- til 10-leddet heterocycloalkyl), -(C(R13)2)n-(C6-Cioaryl) eller -(C(R13)2)n-(5-til 10-leddet heteroaryl); hvor alkylet, cycloalkylet, heterocycloalkylet, arylet eller heteroarylet eventuelt er substitueret med et til fem af R14; hvert R13 uafhængigt er hydrogen, CrC6alkyl, C2-C6alkenyl, C2-C6alkynyl, halogen, cyano, -CF3 eller -OCF3; R14 uafhængigt er hydrogen, -CF3, cyano, halogen eller Ci-6alkyl; hvor alkylet eventuelt er substitueret med en til tre substituenter, som hver uafhængigt er udvalgt fra gruppen bestående af hydroxyl, -CF3, cyano og fluor; og hvert t eller n er et heltal uafhængigt udvalgt fra O, 1, 2 eller 3; hvert z er et heltal uafhængigt udvalgt fra 1 eller 2; hvert y er et heltal uafhængigt udvalgt fra 0,1,2,3 eller 4.
2. Forbindelse ifølge krav 1 eller et farmaceutisk acceptabelt salt deraf, hvor X er imidazolyl, pyrazolyl, isothiazolyl, thiazolyl, isoxazolyl, oxazolyl eller py-ridyl; og R1 er CrC6alkyl.
3. Forbindelse ifølge et af kravene 1 eller 2 eller et farmaceutisk acceptabelt salt deraf, hvor X er imidazolyl; og R1 er methyl.
4. Forbindelse ifølge et af kravene 1 til 3 eller et farmaceutisk acceptabelt salt deraf, hvor z er 1; og R4a og R4b hvert uafhængigt er hydrogen eller methyl.
5. Forbindelse ifølge et af kravene 1 til 4 eller et farmaceutisk acceptabelt salt deraf, hvor R5a, R5b, R6 og R7 uafhængigt er hydrogen.
6. Forbindelse ifølge et af kravene 1 til 5 eller et farmaceutisk acceptabelt salt deraf, hvor y er 0 eller 1; og R2a og R2b uafhængigt er hydrogen eller methyl.
7. Forbindelse ifølge et af de foregående krav eller er et farmaceutisk acceptabelt salt deraf, hvor A er cyclobutyl, cyclopentyl eller cyclohexyl.
8. Forbindelse ifølge et af kravene 1 til 6 eller et farmaceutisk acceptabelt salt deraf, hvor A er dihydroisoxazolyl, tetrahydrofuranyl eller tetrahydropyranyl.
9. Forbindelse ifølge krav 8 eller et farmaceutisk acceptabelt salt deraf, hvor A er tetrahydrofuranyl.
10. Forbindelse ifølge krav 8 eller et farmaceutisk acceptabelt salt deraf, hvor A er tetrahydropyranyl.
11. Forbindelse ifølge et af kravene 6 til 10 eller et farmaceutisk acceptabelt salt deraf, hvor R3 er -(C(R10)2)t-(C6-Cioaryl) eller -(C(R10)2)t-OR12; og t er 0 eller 1.
12. Forbindelse ifølge krav 11 eller et farmaceutisk acceptabelt salt deraf, hvor R3 er -(C(R10)2)t-(C6-Ci0aryl); t er 0; og arylet er phenyl eventuelt substitueret med et til tre R11, hvor R11 er udvalgt fra gruppen bestående af fluor, chlor, -CF3, -SF5, -OR12, CrC3alkyl og C3-C6cycloalkyl; hvor alkylet eller cy-cloalkylet eventuelt og uafhængigt er substitueret med en til tre substituenter udvalgt fra gruppen bestående af halogen og -CF3.
13. Forbindelse ifølge krav 11 eller et farmaceutisk acceptabelt salt deraf, hvor R3 er -(C(R10)2)t-(5- til 10-leddet heteroaryl), og heteroarylet er thiophe-nyl eventuelt substitueret med et til tre R11, hvor R11 er udvalgt fra gruppen bestående af fluor, chlor og -CF3.
14. Forbindelse ifølge krav 11 eller et farmaceutisk acceptabelt salt deraf, hvor R3 er -(C(R10)2)rOR12; t er 0; og R12 er udvalgt fra phenyl, naphthyl eller dihydroindenyl; hvor phenylet, naphthylet eller dihydroindenylet eventuelt og uafhængigt er substitueret med et til tre R14 udvalgt fra gruppen bestående af fluor, chlor, -CF3 og CrC3alkyl; hvor alkylet uafhængigt kan være substitueret med en til tre substituenter udvalgt fra gruppen bestående af halogen og -CF3.
15. Forbindelse ifølge krav 1, hvilken forbindelse har strukturen af formel Id, eller et farmaceutisk acceotabelt salt deraf:
hvor: R2 er hydrogen eller methyl; R3 er -(C(R10)2)r(C6-Cioaryl) eller -(C(R10)2)t-(5-til 10-leddet heteroaryl), hvor arylet eller heteroarylet eventuelt er substitueret med et til tre R11 uafhængigt udvalgt fra gruppen bestående af fluor, chlor, -CF3, -SF5, -OCH3, -OCF3 og -OCFIF2; R10 uafhængigt er hydrogen, halogen, cyano, -CF3, CrC6alkyl eller -SF5; hvor alkylet eventuelt er substitueret med et til tre fluor; og t er 0 eller 1.
16. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor t er 0; og R3 er phenyl eventuelt substitueret med et til tre R11.
17. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor R3 er thiophenyl eventuelt substitueret med et til tre R11.
18. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 7-(4-methyl-1H-imidazol-1-yl)-2-[(1S)-1-{(2S,5/:f)-5-[4-(trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-3,4-dihydro-2H-pyrido[1,2- a] pyrazin-1,6-dion.
19. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-[(1 S)-1-{(2S,5R)-5-[4-chlor-2- (trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-7-(4-methyl-1 H-imidazol-1-yl)-3,4-dihydro-2/-/-pyrido[1,2-a]pyrazin-1,6-dion.
20. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-[(1 S)-1-{(2S,5F?)-5-[3,5-difluor-4- (trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-7-(4-methyl-1 /-/-imidazol-1-yl)-3,4-dihydro-2/-/-pyrido[1,2-a]pyrazin-1,6-dion.
21. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-{(1 S)-1-[(2S,5F?)-5-(4-chlor-3,5- difluorphenyl)tetrahydrofuran-2-yl]ethyl}-7-(4-methyl-1 H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazin-1,6-dion.
22. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-[(1 S)-1-{(2S,5F?)-5-[4,5-difluor-2- (trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-7-(4-methyl-1 H-imidazol-1- yl)-3,4-dihydro-2/-/-pyrido[1,2-a]pyrazin-1,6-dion.
23. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-((15)-1-((25,55)-5-(44^0^2- (trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-7-(4-methyl-1 H-imidazol-1-yl)-3,4-dihydro-2H-pyrido[1,2-a]pyrazin-1,6-dion.
24. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-[(1 S)-1-{(2S,55)-5-[4-chlor-5-fluor-2- (trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-7-(4-methyl-1 H-imidazol-1-yl)-3,4-dihydro-2/-/-pyrido[1,2-a]pyrazin-1,6-dion.
25. Forbindelse ifølge krav 15 eller et farmaceutisk acceptabelt salt deraf, hvor forbindelsen er 2-[(1 S)-1 -{(2S,5/=?)-5-[4-chlor-3-fluor-2- (trifluormethyl)phenyl]tetrahydrofuran-2-yl}ethyl]-7-(4-methyl-1 H-imidazol-1-yl)-3,4-dihydro-2/-/-pyrido[1,2-a]pyrazin-1,6-dion.
26. Forbindelse ifølge et af kravene 1 til 25 eller et farmaceutisk acceptabelt salt deraf, til anvendelse inden for behandlingen af neurodegeneration og psykiatriske sygdomme, herunder Alzheimers sygdom eller Niemann-Pick type C-sygdom.
27. Farmaceutisk sammensætning omfattende en forbindelse ifølge et af kravene 1 til 25 eller et farmaceutisk acceptabelt salt deraf og et farmaceutisk acceptabelt hjælpestof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261703969P | 2012-09-21 | 2012-09-21 | |
PCT/IB2013/058347 WO2014045156A1 (en) | 2012-09-21 | 2013-09-06 | Novel bicyclic pyridinones |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2897956T3 true DK2897956T3 (da) | 2017-01-16 |
Family
ID=49585452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK13792085.6T DK2897956T3 (da) | 2012-09-21 | 2013-09-06 | Nye bicykliske pyridinoner |
Country Status (47)
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
CA2889249C (en) | 2012-12-20 | 2021-02-16 | Francois Paul Bischoff | Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
EP2945944B1 (en) | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
ES2742078T3 (es) * | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
US10562897B2 (en) | 2014-01-16 | 2020-02-18 | Janssen Pharmaceutica Nv | Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators |
KR101886945B1 (ko) * | 2014-04-01 | 2018-08-08 | 화이자 인코포레이티드 | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 |
MX368391B (es) * | 2015-02-03 | 2019-09-30 | Pfizer | Ciclopropabenzofuranil-piridopirazindionas novedosas. |
US9802927B2 (en) | 2015-06-10 | 2017-10-31 | Denali Therapeutics, Inc. | Oxadiazine compounds and methods of use thereof |
JP7018026B2 (ja) | 2016-06-16 | 2022-02-09 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ヘテロアリールエストロゲン受容体モジュレーター及びその使用 |
JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス, インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
CA3114113A1 (en) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Pharmaceutical compositions and methods related to otic therapeutic agents |
CN114340611A (zh) | 2019-04-08 | 2022-04-12 | 频率医疗公司 | 用于治疗听力损失的chir99021和丙戊酸的组合 |
TW202128675A (zh) | 2019-12-06 | 2021-08-01 | 美商維泰克斯製藥公司 | 作為鈉通道調節劑之經取代四氫呋喃 |
CN113402490B (zh) * | 2021-03-29 | 2023-01-03 | 白银京宇新药业有限公司 | 一种1,2,6,7-四氢-8H-茚并[5,4-b]呋喃-8-酮的制备方法 |
US11827627B2 (en) | 2021-06-04 | 2023-11-28 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
CN114034792A (zh) * | 2021-11-09 | 2022-02-11 | 山东新华制药股份有限公司 | 检测氯酮含量的液相色谱分析方法 |
Family Cites Families (134)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1419789A (en) | 1972-08-02 | 1975-12-31 | Pfizer | 2-trifluoromethyl-4-quinolinols |
WO1992000075A1 (en) | 1990-06-29 | 1992-01-09 | Pfizer Inc. | Pyridopyrazine derivatives for treating substance abuse and addiction |
US5482967A (en) | 1992-09-04 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Condensed heterocyclic compounds, their production and use |
DE69432629T3 (de) | 1993-01-25 | 2008-01-17 | Takeda Pharmaceutical Co. Ltd. | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung |
ATE242243T1 (de) | 1995-03-24 | 2003-06-15 | Takeda Chemical Industries Ltd | Zyklische verbindungen, ihre herstellung und ihre verwendung als tachykininrezeptorantagonisten |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
EP2305709A1 (en) | 1997-04-09 | 2011-04-06 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
EP1060141B1 (en) | 1998-03-03 | 2002-10-30 | PPG Industries Ohio, Inc. | Impregnated glass fiber strands and products including the same |
US20020132817A1 (en) | 1998-03-19 | 2002-09-19 | Hideaki Natsugari | Heterocyclic compounds, their production and use |
CA2352612A1 (en) | 1998-11-27 | 2000-06-08 | Hideo Fukui | Pharmaceuticals |
CN101670105B (zh) | 2000-02-24 | 2014-08-06 | 华盛顿大学 | 螯合淀粉样蛋白β肽的人源化抗体 |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
EP1335738A4 (en) | 2000-11-03 | 2004-09-08 | Proteotech Inc | METHODS OF ISOLATING AMYLOID INHIBITOR COMPOUNDS AND USE OF COMPOUNDS USED FROM UNCARIA TOMENTOSA AND PARENT PLANTS |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
CA2498111A1 (en) | 2002-09-11 | 2004-03-25 | Merck & Co., Inc. | Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors |
CA2501799C (en) | 2002-10-09 | 2008-06-17 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
US20040146512A1 (en) | 2002-10-09 | 2004-07-29 | Arnon Rosenthal | Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof |
AU2003301439A1 (en) | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
MXPA05013770A (es) | 2003-06-19 | 2006-03-08 | Pfizer Prod Inc | Antagonista de neuroquinina 1. |
BRPI0413709A (pt) | 2003-08-21 | 2006-10-17 | Pfizer Prod Inc | compostos para o tratamento de distúrbios neurodegenerativos |
CA2538220A1 (en) | 2003-09-09 | 2005-03-24 | Takeda Pharmaceutical Company Limited | Use of antibody |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
WO2005072361A2 (en) | 2004-01-28 | 2005-08-11 | Merck & Co., Inc. | Aminocyclopentyl pyridopyrazinone modulators of chemokine receptor activity |
BRPI0507374A (pt) | 2004-02-02 | 2007-07-10 | Pfizer Prod Inc | moduladores do receptor de histamina-3 |
AU2005227258A1 (en) | 2004-03-09 | 2005-10-06 | Merck & Co., Inc. | HIV integrase inhibitors |
RS50595B (sr) | 2004-03-23 | 2010-05-07 | Pfizer Products Incorporated | Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja |
CA2562713A1 (en) | 2004-04-14 | 2005-12-15 | Gilead Sciences, Inc. | Phosphonate analogs of hiv integrase inhibitor compounds |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
MX2007000998A (es) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
FR2877015B1 (fr) | 2004-10-21 | 2007-10-26 | Commissariat Energie Atomique | Revetement nanostructure et procede de revetement. |
US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
US7741315B2 (en) | 2005-05-10 | 2010-06-22 | Merck Sharp & Dohme Corp. | HIV integrase inhibitors |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
CA2603830A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Co Llc | PYRIDINE [2,3-B] PYRAZINONES |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
CA2607499C (en) | 2005-06-22 | 2010-11-30 | Pfizer Products Inc. | Histamine-3 receptor antagonists |
US20070060534A1 (en) | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
US20070197532A1 (en) | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
US20080275251A1 (en) | 2005-11-18 | 2008-11-06 | Glaxo Group Limited | Novel Intermediates and Their Use |
NZ568050A (en) | 2005-11-24 | 2010-09-30 | Eisai R&D Man Co Ltd | Morpholine type cinnamide compound |
US20070117839A1 (en) | 2005-11-24 | 2007-05-24 | Eisai R&D Management Co., Ltd. | Two cyclic cinnamide compound |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
CN102702044A (zh) | 2006-01-20 | 2012-10-03 | 先灵公司 | 作为γ分泌酶抑制剂的碳环和杂环芳基砜化合物 |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
TWI378091B (en) | 2006-03-09 | 2012-12-01 | Eisai R&D Man Co Ltd | Multi-cyclic cinnamide derivatives |
US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
ATE513831T1 (de) | 2006-04-21 | 2011-07-15 | Pfizer Prod Inc | Pyridinä3,4-büpyrazinone |
AU2007254325B2 (en) | 2006-05-15 | 2012-05-10 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
US20090306054A1 (en) | 2006-05-16 | 2009-12-10 | Gilead Sciences ,Inc. | Integrase inhibitors |
EP2019093A4 (en) | 2006-05-19 | 2011-02-23 | Eisai R&D Man Co Ltd | CINEMA ACID AMID DERIVATIVE FROM THE UREA TYPE |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
CN101631545B (zh) | 2007-01-22 | 2013-03-13 | 辉瑞产品公司 | 治疗性化合物的甲苯磺酸盐及其药物组合物 |
WO2008100412A1 (en) | 2007-02-12 | 2008-08-21 | Merck & Co., Inc. | Piperidine derivatives |
EP2121633A2 (en) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazine derivatives for treatment of ad and related conditions |
TW200848054A (en) | 2007-02-28 | 2008-12-16 | Eisai R&D Man Co Ltd | Two cyclic oxomorpholine derivatives |
WO2008137102A2 (en) | 2007-05-04 | 2008-11-13 | Torreypines Therapeutics, Inc. | Methods of modulating amyloid beta and compounds useful therefor |
RU2009144998A (ru) | 2007-05-07 | 2011-06-20 | Шеринг Корпорейшн (US) | Модуляторы гамма-секретазы |
BRPI0811993A2 (pt) | 2007-05-11 | 2014-11-18 | Hoffmann La Roche | " hetarilanilinas como moduladores para beta-amiloide ". |
CL2008001540A1 (es) | 2007-05-29 | 2009-05-22 | Sgx Pharmaceuticals Inc | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. |
MX2009013131A (es) | 2007-06-01 | 2010-01-15 | Schering Corp | Moduladores de gamma secretasa. |
EP2164852A2 (en) | 2007-06-01 | 2010-03-24 | Schering Corporation | Gamma secretase modulators |
EP2166854A4 (en) | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZOLE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND ASSOCIATED STATES |
WO2009005729A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Gamma secretase modulators |
JP2010535762A (ja) | 2007-08-06 | 2010-11-25 | シェーリング コーポレイション | ガンマセクレターゼモジュレーター |
US7935815B2 (en) | 2007-08-31 | 2011-05-03 | Eisai R&D Management Co., Ltd. | Imidazoyl pyridine compounds and salts thereof |
MX2010002098A (es) | 2007-08-31 | 2010-03-30 | Eisai R&D Man Co Ltd | Compuesto policiclico. |
CA2698341A1 (en) | 2007-09-06 | 2009-03-12 | Schering Corporation | Gamma secretase modulators |
WO2009045314A1 (en) | 2007-09-28 | 2009-04-09 | Schering Corporation | Gamma secretase modulators |
GB0720444D0 (en) | 2007-10-18 | 2007-11-28 | Glaxo Group Ltd | Novel compounds |
JP2011503002A (ja) | 2007-11-05 | 2011-01-27 | シェーリング コーポレイション | γセクレターゼ調節剤 |
JP2011506336A (ja) * | 2007-12-06 | 2011-03-03 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
CN101970433A (zh) | 2007-12-11 | 2011-02-09 | 先灵公司 | γ分泌酶调节剂 |
WO2009076352A1 (en) | 2007-12-11 | 2009-06-18 | Schering Corporation | Gamma secretase modulators |
CA2707492A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
KR101244517B1 (ko) | 2008-01-11 | 2013-03-18 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타에 대한 조절제 |
CA2713716A1 (en) | 2008-02-22 | 2009-08-27 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
CA2716747A1 (en) | 2008-02-29 | 2009-09-03 | Schering Corporation | Gamma secretase modulators for the treatment of alzheimer's disease |
US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
BRPI0912539A2 (pt) | 2008-05-05 | 2015-10-13 | Amgen Inc | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. |
FR2933700B1 (fr) * | 2008-07-08 | 2010-07-30 | Sanofi Aventis | Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique |
TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
EP2312945A4 (en) | 2008-08-13 | 2012-05-09 | Merck Sharp & Dohme | PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER |
WO2010019393A1 (en) | 2008-08-13 | 2010-02-18 | Merck Sharp & Dohme Corp. | Pyrimidine derivatives for treatment of alzheimer's disease |
CA2733606A1 (en) | 2008-08-27 | 2010-03-04 | Eisai R&D Management Co., Ltd. | Process for preparing certain cinnamide compounds |
WO2010040661A1 (en) | 2008-10-09 | 2010-04-15 | F. Hoffmann-La Roche Ag | Modulators for amyloid beta |
AU2009313524A1 (en) | 2008-11-06 | 2010-05-14 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
US20120129846A1 (en) | 2008-11-06 | 2012-05-24 | Zhaoning Zhu | Gamma secretase modulators |
BRPI0921317A2 (pt) | 2008-11-06 | 2017-06-06 | Astrazeneca Ab | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero |
KR101293421B1 (ko) | 2008-11-10 | 2013-08-05 | 에프. 호프만-라 로슈 아게 | 헤테로사이클릭 감마 분비효소 조절제 |
WO2010077582A1 (en) | 2008-12-16 | 2010-07-08 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
US8575150B2 (en) | 2008-12-16 | 2013-11-05 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of Alzheimer's disease |
PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
PE20120061A1 (es) | 2008-12-19 | 2012-02-19 | Boehringer Ingelheim Int | Derivados de pirimidina como antagonistas del receptor ccr2 |
JP2012513399A (ja) | 2008-12-22 | 2012-06-14 | シェーリング コーポレイション | γ−セクレターゼ調節剤 |
AU2009330234A1 (en) | 2008-12-22 | 2011-07-07 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
TW201030002A (en) | 2009-01-16 | 2010-08-16 | Bristol Myers Squibb Co | Bicyclic compounds for the reduction of beta-amyloid production |
AP2011005779A0 (en) | 2009-02-06 | 2011-08-31 | Ortho Mcneil Janssen Pharm | Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators. |
TWI461425B (zh) * | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
JP2012051806A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | イミダゾリルピラジン誘導体 |
JP2012051807A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | アリールイミダゾール化合物 |
JP2012051805A (ja) | 2009-02-26 | 2012-03-15 | Eisai R & D Management Co Ltd | テトラヒドロトリアゾロピリジン誘導体の製造方法 |
US8703954B2 (en) | 2009-02-26 | 2014-04-22 | Eisai R&D Management Co., Ltd. | Salt of tetrahydrotriazolopyridine derivative and crystal thereof |
JP2012121809A (ja) | 2009-02-26 | 2012-06-28 | Eisai R & D Management Co Ltd | 多環式化合物の製造法およびその中間体 |
US20120053165A1 (en) | 2009-03-03 | 2012-03-01 | Pfizer Inc. | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators |
CA2768664C (en) | 2009-08-07 | 2016-10-11 | Dow Agrosciences Llc | Pesticidal compositions |
JP2013508350A (ja) * | 2009-10-20 | 2013-03-07 | ファイザー・インク | ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール |
US20120040950A1 (en) * | 2009-12-22 | 2012-02-16 | Vertex Pharmaceuticals Incorporated | Isoindolinone inhibitors of phosphatidylinositol 3-kinase |
WO2012131539A1 (en) * | 2011-03-31 | 2012-10-04 | Pfizer Inc. | Novel bicyclic pyridinones |
AU2013261023B2 (en) * | 2012-05-16 | 2016-11-24 | Cellzome Limited | Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease |
TWI614238B (zh) | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
UA110688C2 (uk) | 2012-09-21 | 2016-01-25 | Пфайзер Інк. | Біциклічні піридинони |
CA2889249C (en) | 2012-12-20 | 2021-02-16 | Francois Paul Bischoff | Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators |
EP2945944B1 (en) | 2013-01-17 | 2016-11-09 | Janssen Pharmaceutica, N.V. | Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators |
ES2742078T3 (es) | 2013-10-04 | 2020-02-13 | Pfizer | Piridonas bicíclicas novedosas como moduladores de gamma-secretasa |
CN115068134A (zh) | 2014-03-21 | 2022-09-20 | 阿莱恩技术有限公司 | 具有弹性体的分段的正畸矫正器 |
KR101886945B1 (ko) | 2014-04-01 | 2018-08-08 | 화이자 인코포레이티드 | 감마-세크레타제 조절제로서의 크로멘 및 1,1a,2,7b-테트라히드로시클로프로파[c]크로멘 피리도피라진디온 |
-
2013
- 2013-06-09 UA UAA201501621A patent/UA110688C2/uk unknown
- 2013-09-05 MA MA37886A patent/MA37886B1/fr unknown
- 2013-09-06 HU HUE13792085A patent/HUE031248T2/en unknown
- 2013-09-06 EP EP13792085.6A patent/EP2897956B1/en active Active
- 2013-09-06 MY MYPI2015700772A patent/MY181891A/en unknown
- 2013-09-06 RS RS20161058A patent/RS55426B1/sr unknown
- 2013-09-06 MD MDA20150023A patent/MD4583B1/ro not_active IP Right Cessation
- 2013-09-06 GE GEAP201313766A patent/GEP201706659B/en unknown
- 2013-09-06 AP AP2015008277A patent/AP2015008277A0/xx unknown
- 2013-09-06 JP JP2015532539A patent/JP5844018B2/ja not_active Expired - Fee Related
- 2013-09-06 PT PT137920856T patent/PT2897956T/pt unknown
- 2013-09-06 LT LTEP13792085.6T patent/LT2897956T/lt unknown
- 2013-09-06 DK DK13792085.6T patent/DK2897956T3/da active
- 2013-09-06 NZ NZ704863A patent/NZ704863A/en not_active IP Right Cessation
- 2013-09-06 ES ES13792085.6T patent/ES2609987T3/es active Active
- 2013-09-06 PE PE2015000380A patent/PE20150686A1/es not_active Application Discontinuation
- 2013-09-06 MX MX2015003637A patent/MX360599B/es active IP Right Grant
- 2013-09-06 IN IN1119DEN2015 patent/IN2015DN01119A/en unknown
- 2013-09-06 CA CA2882386A patent/CA2882386C/en active Active
- 2013-09-06 AU AU2013319845A patent/AU2013319845B2/en not_active Ceased
- 2013-09-06 EA EA201590319A patent/EA026668B1/ru not_active IP Right Cessation
- 2013-09-06 CN CN201380048982.5A patent/CN104662021B/zh not_active Expired - Fee Related
- 2013-09-06 WO PCT/IB2013/058347 patent/WO2014045156A1/en active Application Filing
- 2013-09-06 ME MEP-2016-269A patent/ME02571B/me unknown
- 2013-09-06 BR BR112015006436A patent/BR112015006436A2/pt not_active Application Discontinuation
- 2013-09-06 PL PL13792085T patent/PL2897956T3/pl unknown
- 2013-09-06 KR KR1020157006971A patent/KR101725696B1/ko active IP Right Grant
- 2013-09-06 SG SG11201501074WA patent/SG11201501074WA/en unknown
- 2013-09-06 SI SI201330390T patent/SI2897956T1/sl unknown
- 2013-09-17 TW TW102133670A patent/TWI500616B/zh not_active IP Right Cessation
- 2013-09-19 US US14/031,163 patent/US8916564B2/en active Active
- 2013-09-19 AR ARP130103367A patent/AR092628A1/es unknown
- 2013-09-19 UY UY0001035039A patent/UY35039A/es not_active Application Discontinuation
-
2014
- 2014-11-17 US US14/543,020 patent/US9193726B2/en active Active
-
2015
- 2015-02-05 CR CR20150053A patent/CR20150053A/es unknown
- 2015-02-09 IL IL237163A patent/IL237163A/en active IP Right Grant
- 2015-02-20 PH PH12015500376A patent/PH12015500376B1/en unknown
- 2015-02-20 ZA ZA2015/01195A patent/ZA201501195B/en unknown
- 2015-03-06 CU CUP2015000021A patent/CU20150021A7/es unknown
- 2015-03-06 TN TNP2015000084A patent/TN2015000084A1/fr unknown
- 2015-03-19 NI NI201500038A patent/NI201500038A/es unknown
- 2015-03-20 GT GT201500069A patent/GT201500069A/es unknown
- 2015-03-20 DO DO2015000069A patent/DOP2015000069A/es unknown
- 2015-03-20 CL CL2015000717A patent/CL2015000717A1/es unknown
- 2015-04-20 EC ECIEPI201515594A patent/ECSP15015594A/es unknown
- 2015-07-07 HK HK15106474.5A patent/HK1206013A1/zh not_active IP Right Cessation
- 2015-10-07 US US14/877,118 patent/US9751877B2/en active Active
-
2016
- 2016-11-22 HR HRP20161558TT patent/HRP20161558T1/hr unknown
- 2016-12-14 CY CY20161101290T patent/CY1118662T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2897956T3 (da) | Nye bicykliske pyridinoner | |
US9067934B2 (en) | Bicyclic pyridinones | |
AU2015242330B2 (en) | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
US9765073B2 (en) | Cyclopropabenzofuranyl pyridopyrazinediones | |
EP3052495B1 (en) | Novel bicyclic pyridinones as gamma-secretase modulators | |
OA18546A (en) | Novel cyclopropabenzofuranyl pyridopyrazinediones. | |
OA18058A (en) | Chromene and 1,1 A,2,7B-tetrahydrocyclopropa[C]chromene pyridopyrazinediones as gamma-secretase modulators. |